12,372 trials
Childhood Acute Promyelocytic Leukemia With PML-RARA · Myeloid Neoplasm
Primary: Event-free Survival (EFS) — 95.4; 82.9 Percentage of participants
Type 2 Diabetes
Primary: MYCL — 0.54; 0.44; 0.35; 0.36 percentage of water signal
Plaque Psoriasis
Primary: Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 16 — 32.4; 43.6; 57.9 percentage of participants — p=0.027
Chronic Pain · Low Back Pain · Analgesia
Primary: Change in Weekly Average Electronic Diary (eDiary) Numeric Rating Scale -Pain (NRS-Pain) Score From Randomization Baseline to Final 2 Weeks (Average of Weeks 11 and 12)…
Breast Cancer · Hot Flashes · Menopausal Symptoms
Primary: To Evaluate the Efficacy of Flaxseed on Hot Flash Scores in Women as Measured by a Daily Prospective Hot Flash Diary. — -4.9; -3.5 units on a scale — p=0.29
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to End — -0.54 HbA1c in percent — p=<0.02
Infections, Streptococcal
Primary: Number of Seroprotected Subjects Against Pneumococcal Serotypes — 149; 149; 150; 152 Subjects
Hyperparathyroidism, Secondary
Primary: Percentage of Participants With Serum Corrected Calcium < 7.5 mg/dL During the 4-week Treatment Period — 0.7 percentage of participants
Breast Cancer
Primary: Time to Tumor Progression — 13.5; 15.0 months — p=0.007
Breast Cancer · Infertility · Menopausal Symptoms
Primary: Rate of Premature Ovarian Failure at 2 Years — 15; 5 Participants
Anemia
Primary: Percentage of Participants With Response to Treatment — 50.8 percentage of participants
Neoplasms
Primary: On-Study Duration of Trial Treatment — 386.0 days
Carcinoma, Non-Small-Cell Lung
Primary: Safety Assesment — 92.9; 35.7; 35.7; 21.4 Percentage of participants
Dyslipidemias
Primary: Peak Oxygen Consumption — 43.8; 51.6; 53.5 percentage of predicted value
AtrioVentricular Nodal Reentrant Tachycardia · Supraventricular Tachycardia · Heart Disease
Primary: Chronic Effectiveness (Through 6 Months) of the Freezor Xtra Catheter for the Treatment of AVNRT Using an Endocardial Approach. — 368; 29 Participants — p=<0.0001